• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

弥漫性低级别胶质瘤不同恶性转化模式的特征及其临床意义。

Characterization and clinical implications of different malignant transformation patterns in diffuse low-grade gliomas.

机构信息

Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, China.

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

出版信息

Cancer Sci. 2023 Sep;114(9):3708-3718. doi: 10.1111/cas.15889. Epub 2023 Jun 18.

DOI:10.1111/cas.15889
PMID:37332121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10475770/
Abstract

Malignant transformation (MT) of low-grade gliomas (LGGs) to a higher-grade variant seems inevitable, yet it remains unclear which LGG patients will progress to grade 3 or even directly to grade 4 after receiving a long course of treatment. To elucidate this, we conducted a retrospective cohort study based on 229 adults with recurrent LGG. Our study aimed to disclose the characteristics of different MT patterns and to build predictive models for patients with LGG. Patients were allocated into group 2-2 (n = 81, 35.4%), group 2-3 (n = 91, 39.7%), and group 2-4 (n = 57, 24.9%), based on their MT patterns. Patients who underwent MT showed lower Karnofsky performance scale (KPS) scores, larger tumor sizes, smaller extents of resection (EOR), higher Ki-67 indices, lower rates of 1p/19q codeletion, but higher rates of subventricular involvement, radiotherapy, chemotherapy, astrocytoma, and post-progression enhancement (PPE) compared with those in group 2-2 (p < 0.01). On multivariate logistic regression, 1p/19q codeletion, Ki-67 index, radiotherapy, EOR, and KPS score were independently associated with MT (p < 0.05). Survival analyses demonstrated that patients in group 2-2 had the longest survival, followed by group 2-3 and then group 2-4 (p < 0.0001). Based on these independent parameters, we constructed a nomogram model that exhibited superior potential (sensitivity: 0.864, specificity: 0.814, and accuracy: 0.843) compared with PPE in early prediction of MT. Combining the factors of 1p/19q codeletion, Ki-67 index, radiotherapy, EOR, and KPS score that were presented at initial diagnosis could precisely forecast the subsequent MT patterns of patients with LGG.

摘要

低级别胶质瘤(LGG)向高级别变异的恶性转化(MT)似乎不可避免,但仍不清楚哪些 LGG 患者在接受长期治疗后会进展为 3 级甚至直接进展为 4 级。为了阐明这一点,我们对 229 例复发性 LGG 成人患者进行了回顾性队列研究。我们的研究旨在揭示不同 MT 模式的特征,并为 LGG 患者建立预测模型。根据 MT 模式,患者被分为 2-2 组(n=81,35.4%)、2-3 组(n=91,39.7%)和 2-4 组(n=57,24.9%)。与 2-2 组相比,MT 患者的卡氏功能状态评分(KPS)较低,肿瘤较大,切除范围(EOR)较小,Ki-67 指数较高,1p/19q 缺失率较低,但脑室下侵犯、放疗、化疗、星形细胞瘤和进展后增强(PPE)的发生率较高(p<0.01)。多变量逻辑回归分析显示,1p/19q 缺失、Ki-67 指数、放疗、EOR 和 KPS 评分与 MT 独立相关(p<0.05)。生存分析表明,2-2 组患者的生存时间最长,其次是 2-3 组,然后是 2-4 组(p<0.0001)。基于这些独立参数,我们构建了一个列线图模型,与早期 PPE 相比,该模型具有更好的预测能力(敏感性:0.864,特异性:0.814,准确性:0.843)。结合初诊时出现的 1p/19q 缺失、Ki-67 指数、放疗、EOR 和 KPS 评分等因素,可以准确预测 LGG 患者后续 MT 模式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/10475770/c093e2532a25/CAS-114-3708-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/10475770/d33c357be273/CAS-114-3708-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/10475770/8e018f9e9531/CAS-114-3708-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/10475770/d201bce2be0d/CAS-114-3708-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/10475770/ec6bd4d3d643/CAS-114-3708-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/10475770/c093e2532a25/CAS-114-3708-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/10475770/d33c357be273/CAS-114-3708-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/10475770/8e018f9e9531/CAS-114-3708-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/10475770/d201bce2be0d/CAS-114-3708-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/10475770/ec6bd4d3d643/CAS-114-3708-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/10475770/c093e2532a25/CAS-114-3708-g001.jpg

相似文献

1
Characterization and clinical implications of different malignant transformation patterns in diffuse low-grade gliomas.弥漫性低级别胶质瘤不同恶性转化模式的特征及其临床意义。
Cancer Sci. 2023 Sep;114(9):3708-3718. doi: 10.1111/cas.15889. Epub 2023 Jun 18.
2
Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.染色体臂 1p 和 19q 缺失的检测在胶质瘤患者中的诊断准确性和成本效益。
Cochrane Database Syst Rev. 2022 Mar 2;3(3):CD013387. doi: 10.1002/14651858.CD013387.pub2.
3
Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update.神经外科医生大会关于化疗在成人新诊断的世界卫生组织二级弥漫性胶质瘤中作用的系统评价和循证指南:更新版
J Neurooncol. 2025 Jan;171(2):279-298. doi: 10.1007/s11060-024-04861-6. Epub 2024 Nov 20.
4
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.首次就诊时磁共振灌注成像用于鉴别低级别与高级别胶质瘤
Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011551. doi: 10.1002/14651858.CD011551.pub2.
5
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
6
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
7
Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of radiotherapy in the management of patients with diffuse low grade glioma in adults: update.神经外科医师大会关于放射治疗在成人弥漫性低级别胶质瘤患者管理中作用的系统评价和循证指南:更新版
J Neurooncol. 2025 Jul 24. doi: 10.1007/s11060-025-05074-1.
8
Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas.低级别胶质瘤治疗中术后早期放疗与延迟放疗的比较。
Cochrane Database Syst Rev. 2015 Jun 29;6(6):CD009229. doi: 10.1002/14651858.CD009229.pub2.
9
Prediction of 1p/19q state in glioma by integrated deep learning method based on MRI radiomics.基于MRI影像组学的集成深度学习方法预测胶质瘤中的1p/19q状态
BMC Cancer. 2025 Jul 28;25(1):1228. doi: 10.1186/s12885-025-14454-9.
10
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.

引用本文的文献

1
Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas.病例报告:替莫唑胺诱导的高突变率表明胶质母细胞瘤患者对免疫治疗的反应不佳。
Front Immunol. 2024 Apr 4;15:1369972. doi: 10.3389/fimmu.2024.1369972. eCollection 2024.
2
TBX15 facilitates malignant progression of glioma by transcriptional activation of TXDNC5.TBX15通过转录激活TXDNC5促进胶质瘤的恶性进展。
iScience. 2024 Jan 18;27(2):108950. doi: 10.1016/j.isci.2024.108950. eCollection 2024 Feb 16.

本文引用的文献

1
Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort study.RANO-PRO工作组标准化优先级结构与恶性胶质瘤患者疾病进展之间的关系:一项回顾性队列研究。
EClinicalMedicine. 2022 Nov 12;55:101718. doi: 10.1016/j.eclinm.2022.101718. eCollection 2023 Jan.
2
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.美国 2015-2019 年确诊的原发性脑和其他中枢神经系统肿瘤 CBTRUS 统计报告。
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95. doi: 10.1093/neuonc/noac202.
3
Malignant Progression of Diffuse Low-grade Gliomas: A Systematic Review and Meta-analysis on Incidence and Related Factors.
弥漫性低级别胶质瘤的恶性进展:发病率及相关因素的系统评价和荟萃分析。
Neurol Med Chir (Tokyo). 2022 Apr 15;62(4):177-185. doi: 10.2176/jns-nmc.2021-0313. Epub 2022 Feb 22.
4
Prediction of Malignant Transformation of WHO II Astrocytoma Using Mathematical Models Incorporating Apparent Diffusion Coefficient and Contrast Enhancement.使用结合表观扩散系数和对比增强的数学模型预测世界卫生组织II级星形细胞瘤的恶性转化
Front Oncol. 2021 Sep 29;11:744827. doi: 10.3389/fonc.2021.744827. eCollection 2021.
5
Systematic review-Time to malignant transformation in low-grade gliomas: Predicting a catastrophic event with clinical, neuroimaging, and molecular markers.系统评价——低级别胶质瘤发生恶性转化的时间:利用临床、神经影像学和分子标志物预测灾难性事件
Neurooncol Adv. 2021 Jul 27;3(1):vdab101. doi: 10.1093/noajnl/vdab101. eCollection 2021 Jan-Dec.
6
Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas.数学建模和突变分析揭示了预防 II 级 IDH 突变型胶质瘤恶变的最佳治疗方法。
Cancer Res. 2021 Sep 15;81(18):4861-4873. doi: 10.1158/0008-5472.CAN-21-0985. Epub 2021 Jul 31.
7
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类:概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
8
Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastoma.联合 MGMT 启动子焦磷酸测序和蛋白表达优化胶质母细胞瘤的预后分层。
Cancer Sci. 2021 Sep;112(9):3699-3710. doi: 10.1111/cas.15024. Epub 2021 Jul 2.
9
Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study.免疫治疗联合放疗治疗复发性恶性脑胶质瘤:一项前瞻性研究结果。
Front Immunol. 2021 May 7;12:632547. doi: 10.3389/fimmu.2021.632547. eCollection 2021.
10
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.替莫唑胺诱导的超突变与 IDH 突变型低级别胶质瘤高级别转化后的远处复发和生存降低有关。
Neuro Oncol. 2021 Nov 2;23(11):1872-1884. doi: 10.1093/neuonc/noab081.